Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dainippon Sumitomo Prepares 2011 Schizophrenia Drug Launch In The U.S.

This article was originally published in PharmAsia News

Executive Summary

Major Japanese drug maker Dainippon Sumitomo will establish a holding company in the U.S. in July to prepare for an NDA submission to U.S. FDA for novel schizophrenia drug lurasidone (SM-13496). The company plans to submit the NDA for the antipsychotic agent with FDA in the first half of 2010, said President Masayo Tata, June 15. According to Dainippon Sumitomo, late-stage clinical trials for lurasidone resulted in promising results in confirming the drug's efficacy and safety, which prompted the company to move up the planned launch date in the U.S. from 2012 to 2011. (Click here for more - Japanese Language

You may also be interested in...



Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says

Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’

Health And Wellness Trademark Review 22 September, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel